Company intelligence / Profile preview

Suzhou Lanma Medical Technology Co., Ltd.

Suzhou, Jiangsu Sheng, Chinaen.lanmabio.com ↗

Ownership: Private
Development stage: Other

Overview

Suzhou Lanma Medical Technology is conducting early-phase clinical trials of its lead product LM103, an autologous TIL therapy. The first investigator-sponsored trial has dosed its initial patient. The company is evaluating safety, tolerability, immune response, and preliminary efficacy in patients with advanced solid tumors. No published efficacy data yet; studies are not yet recruiting or just beginning enrollment as of mid/late 2024.

Therapeutic areas: Oncology
Modalities: Tumor Infiltrating Lymphocytes (TILs)Cell therapy
Industry: Biotech

Drug pipeline

7 assets

LM103

6 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Suzhou Lanma Medical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Lanma Medical Technology Co., Ltd..

Explore the full profile